Home › Companies › MERSANA THERAPEUTICS INC. › 2023-2024
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and MERSANA THERAPEUTICS INC.’s Form 8-K, filed June 11, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 11, 2024: 4 items on MERSANA THERAPEUTICS INC.’s Form 8-K, filed June 11, 2024: 2 elected · 2 approved.
Notable dissent: 1 director (13.1% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025
Explore MERSANA THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are MERSANA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 11, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Willard H. Dere, M.D. | 84,576,414 | 12,733,786 | 104,329 | -- | 8,260,872 | 87% | Elected | — |
| Elect Director: Martin Huber, M.D. | 96,836,592 | 472,410 | 105,527 | -- | 8,260,872 | 99.5% | Elected | — |
| 2. Advisory Vote on Executive Compensation | 96,316,340 | 984,371 | 113,818 | -- | 8,260,872 | 99% | Approved | — |
| 3. Ratification of Selection of Independent Registered Public Accounting Firm | 105,233,670 | 323,020 | 118,711 | -- | -- | 99.7% | Approved | — |
Source: MERSANA THERAPEUTICS INC., Form 8-K, filed with the SEC on June 11, 2024 — read the filing on EDGAR.
See voting trends for Health Care companies, 2023-2024: shareholder support by sector and by company size.
140 asset managers disclosed a vote on at least one MERSANA THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 2 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors, each to serve until the 2027 Annual Meeting of Stockholders: Martin Huber, M.D.
MERSANA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Martin Huber, M.D.”): 96,836,592 for, 472,410 against, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The Company's stockholders elected the two persons listed below as Class I directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 42 asset managers below reported 19,708,581 for, 14,464 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,218,949 | 0 | 0 | 0 | For |
| BlackRock | 4,058,042 | 0 | 0 | 0 | For |
| State Street | 3,015,686 | 4,719 | 0 | 0 | For |
| Fidelity | 2,416,647 | 0 | 0 | 0 | For |
| JPMorgan | 949,330 | 0 | 0 | 0 | For |
| Equitable | 351,584 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 333,424 | 0 | 0 | 0 | For |
| Charles Schwab | 295,872 | 0 | 0 | 0 | For |
| Invesco | 291,363 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 232,300 | 0 | 0 | 0 | For |
| SEI | 212,020 | 0 | 0 | 0 | For |
| Lincoln Financial | 168,180 | 2,209 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 161,956 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 150,000 | 0 | 0 | 0 | For |
| Voya | 144,037 | 0 | 0 | 0 | For |
| TIAA | 117,317 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 91,080 | 0 | 0 | 0 | For |
| ProShares | 71,514 | 0 | 0 | 0 | For |
| ETF Series Solutions | 57,347 | 0 | 0 | 0 | For |
| John Hancock | 41,953 | 0 | 0 | 0 | For |
| Pacific Life | 41,846 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 40,200 | 0 | 0 | 0 | For |
| New York Life | 29,740 | 0 | 0 | 0 | For |
| Nationwide | 29,622 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 28,866 | 0 | 0 | 0 | For |
Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors, each to serve until the 2027 Annual Meeting of Stockholders: Willard H. Dere, M.D.
MERSANA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Willard H. Dere, M.D.”): 84,576,414 for, 12,733,786 against, per its Form 8-K filed June 11, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 - Election of Directors The Company's stockholders elected the two persons listed below as Class I directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 42 asset managers below reported 17,894,798 for, 1,828,247 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,207,238 | 11,711 | 0 | 0 | For |
| BlackRock | 4,058,042 | 0 | 0 | 0 | For |
| State Street | 2,976,654 | 43,751 | 0 | 0 | For |
| Fidelity | 2,405,947 | 10,700 | 0 | 0 | For |
| JPMorgan | 949,330 | 0 | 0 | 0 | For |
| Equitable | 182,774 | 168,810 | 0 | 0 | Mixed |
| Direxion Shares ETF Trust | 0 | 333,424 | 0 | 0 | Against |
| Charles Schwab | 295,872 | 0 | 0 | 0 | For |
| Invesco | 0 | 291,363 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 232,300 | 0 | 0 | Against |
| SEI | 212,020 | 0 | 0 | 0 | For |
| Lincoln Financial | 168,180 | 2,209 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 161,956 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 150,000 | 0 | 0 | Against |
| Voya | 0 | 144,037 | 0 | 0 | Against |
| TIAA | 117,317 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 91,080 | 0 | 0 | Against |
| ProShares | 0 | 71,514 | 0 | 0 | Against |
| ETF Series Solutions | 0 | 57,347 | 0 | 0 | Against |
| John Hancock | 0 | 41,953 | 0 | 0 | Against |
| Pacific Life | 41,846 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 0 | 40,200 | 0 | 0 | Against |
| New York Life | 29,740 | 0 | 0 | 0 | For |
| Nationwide | 1,065 | 28,557 | 0 | 0 | Against |
| Bridge Builder Trust | 28,866 | 0 | 0 | 0 | For |
Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
99% Approved · of votes cast
Prior year: 76.9% for (June 8, 2023 meeting) ▲ 22.1 pts
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.
MERSANA THERAPEUTICS INC.’s own tally for this item (“2. Advisory Vote on Executive Compensation”): 96,316,340 for, 984,371 against — passed, per its Form 8-K filed June 11, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Advisory Vote on Executive Compensation The Company's stockholders approved Proposal 2.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,218,949 | 0 | 0 | 0 | For |
| BlackRock | 4,058,042 | 0 | 0 | 0 | For |
| State Street | 3,020,405 | 0 | 0 | 0 | For |
| Fidelity | 2,416,647 | 0 | 0 | 0 | For |
| JPMorgan | 949,330 | 0 | 0 | 0 | For |
| Equitable | 351,584 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 333,424 | 0 | 0 | 0 | For |
| Charles Schwab | 295,872 | 0 | 0 | 0 | For |
| Invesco | 0 | 291,363 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 232,300 | 0 | 0 | 0 | For |
| SEI | 212,020 | 0 | 0 | 0 | For |
| Lincoln Financial | 170,389 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 161,956 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 150,000 | 0 | 0 | 0 | For |
| Voya | 144,037 | 0 | 0 | 0 | For |
| TIAA | 117,317 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 91,080 | 0 | 0 | 0 | For |
| ProShares | 71,514 | 0 | 0 | 0 | For |
| ETF Series Solutions | 57,347 | 0 | 0 | 0 | For |
| John Hancock | 41,953 | 0 | 0 | 0 | For |
| Pacific Life | 41,846 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 40,200 | 0 | 0 | 0 | For |
| New York Life | 29,740 | 0 | 0 | 0 | For |
| Nationwide | 29,622 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 28,866 | 0 | 0 | 0 | For |
Fund voting reports, all 42 managers: 19,421,786 for, 301,259 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 19,364,688 | 0 | 0 | 0 | For |
| VR Adviser, LLC | 11,328,000 | 0 | 0 | 0 | For |
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | 0 | 0 | 0 | For |
| State Street | 5,229,182 | 0 | 0 | 0 | For |
| BlackRock | 3,491,446 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 3,046,782 | 0 | 0 | 0 | For |
| Woodline Partners LP | 2,934,622 | 0 | 0 | 0 | For |
| Citadel | 2,642,768 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,346,362 | 0 | 0 | 0 | For |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2,196,111 | 0 | 0 | 0 | For |
| Cormorant Asset Management, LP | 1,863,681 | 0 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 1,444,981 | 0 | 0 | 0 | For |
| 5AM Venture Management, LLC | 1,305,000 | 0 | 0 | 0 | For |
| DE Shaw | 1,278,087 | 0 | 0 | 0 | For |
| Octagon Capital Advisors LP | 1,000,000 | 0 | 0 | 0 | For |
| Northern Trust | 835,343 | 93 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 767,907 | 0 | 0 | 0 | For |
| Affinity Asset Advisors, LLC | 750,000 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 548,746 | 0 | 0 | 0 | For |
| Wellington | 483,640 | 0 | 0 | 0 | For |
| UBS | 434,293 | 0 | 0 | 0 | For |
| PNC BANK, NATIONAL ASSOCIATION | 414,200 | 0 | 0 | 0 | For |
| Renaissance | 388,639 | 0 | 0 | 0 | For |
| Verition Fund Management LLC | 358,124 | 0 | 0 | 0 | For |
| Rafferty Asset Management, LLC | 333,424 | 0 | 0 | 0 | For |
Institutional-manager reports, all 112 managers: 77,375,840 for, 679,546 against, 71,572 abstained, 28 unknown. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.7% Approved · of votes cast
Prior year: 99.8% for (June 8, 2023 meeting) ▼ 0.2 pts
Description as filed by funds: To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
MERSANA THERAPEUTICS INC.’s own tally for this item (“3. Ratification of Selection of Independent Registered Public Accounting Firm”): 105,233,670 for, 323,020 against — passed, per its Form 8-K filed June 11, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Ratification of Selection of Independent Registered Public Accounting Firm The Company's stockholders approved Proposal 3.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 42 asset managers below reported 19,717,879 for, 5,166 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 6,218,949 | 0 | 0 | 0 | For |
| BlackRock | 4,058,042 | 0 | 0 | 0 | For |
| State Street | 3,015,239 | 5,166 | 0 | 0 | For |
| Fidelity | 2,416,647 | 0 | 0 | 0 | For |
| JPMorgan | 949,330 | 0 | 0 | 0 | For |
| Equitable | 351,584 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 333,424 | 0 | 0 | 0 | For |
| Charles Schwab | 295,872 | 0 | 0 | 0 | For |
| Invesco | 291,363 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 232,300 | 0 | 0 | 0 | For |
| SEI | 212,020 | 0 | 0 | 0 | For |
| Lincoln Financial | 170,389 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 161,956 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 150,000 | 0 | 0 | 0 | For |
| Voya | 144,037 | 0 | 0 | 0 | For |
| TIAA | 117,317 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 91,080 | 0 | 0 | 0 | For |
| ProShares | 71,514 | 0 | 0 | 0 | For |
| ETF Series Solutions | 57,347 | 0 | 0 | 0 | For |
| John Hancock | 41,953 | 0 | 0 | 0 | For |
| Pacific Life | 41,846 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 40,200 | 0 | 0 | 0 | For |
| New York Life | 29,740 | 0 | 0 | 0 | For |
| Nationwide | 29,622 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 28,866 | 0 | 0 | 0 | For |
Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 122,361,236 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 5.08% |
| 2 | BlackRock | 3.32% |
| 3 | State Street | 2.47% |
| 4 | Fidelity | 1.98% |
| 5 | JPMorgan | 0.78% |
| 6 | Equitable | 0.29% |
| 7 | Direxion Shares ETF Trust | 0.27% |
| 8 | Charles Schwab | 0.24% |
| 9 | Invesco | 0.24% |
| 10 | BRIDGEWAY FUNDS INC | 0.19% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | EcoR1 Capital, LLC | 15.83% |
| 2 | VR Adviser, LLC | 9.26% |
| 3 | Bain Capital Life Sciences Investors, LLC | 7.08% |
| 4 | State Street | 4.27% |
| 5 | BlackRock | 2.85% |
| 6 | Rock Springs Capital Management LP | 2.49% |
| 7 | Woodline Partners LP | 2.40% |
| 8 | Citadel | 2.16% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.92% |
| 10 | SILVERARC CAPITAL MANAGEMENT, LLC | 1.79% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Entities affiliated with EcoR1 Capital, LLC | 19,364,688 | 15.83% | Proxy statement (DEF 14A), proxy filed April 26, 2024 |
| Nextech Crossover I SCSp | 12,067,246 | 9.86% | Schedule 13G, filed November 14, 2024 |
| Entities affiliated with Venrock Healthcare Capital Partners III, L.P. | 11,328,000 | 9.26% | Proxy statement (DEF 14A), proxy filed April 26, 2024 |
| Entities affiliated with Balyasny Asset Management L.P. | 9,698,673 | 7.93% | Proxy statement (DEF 14A), proxy filed April 26, 2024 |
| Andrew A. F. Hack, M.D., Ph.D. | 8,876,933 | 7.25% | Proxy statement (DEF 14A), proxy filed April 26, 2024 |
| Entities affiliated with Bain Capital Life Sciences | 8,663,673 | 7.08% | Proxy statement (DEF 14A), proxy filed April 26, 2024 |
| Blackrock, Inc. | 7,844,282 | 6.41% | Proxy statement (DEF 14A), proxy filed April 26, 2024 |
| SilverArc Capital Management, LLC | 6,420,136 | 5.25% | Proxy statement (DEF 14A), proxy filed April 26, 2024 |
| The Vanguard Group | 6,237,588 | 5.10% | Schedule 13G, filed February 13, 2024 |
| State Street | 5,497,443 | 4.49% | Form 13F, quarter ended March 31, 2024 |
Percentages above are of 122,361,236 shares outstanding, as reported by MERSANA THERAPEUTICS INC. on its Form 10-Q dated May 3, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At MERSANA THERAPEUTICS INC.'s shareholder meeting held June 11, 2024, in the 2023-2024 proxy season, 140 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 661 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — MERSANA THERAPEUTICS INC.'s filing reports the proposal as approved, with 99% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: MERSANA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 11, 2024.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from MERSANA THERAPEUTICS INC.’s 10-Q dated May 3, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
MERSANA THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025.
Proxy Votes Now, “MERSANA THERAPEUTICS INC. 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/mersana-therapeutics-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.